Linked Life Data

17089127

Source:http://linkedlifedata.com/resource/pubmed/id/17089127

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-1-11
pubmed:abstractText
The hyper-CVAD + rituximab (R) programme consists of fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone + R alternating with high-dose methotrexate + cytarabine (HD MTX/ARA-C) + R. This regimen, when used as initial therapy for patients under 65 years of age with previously untreated mantle cell lymphoma (MCL), results in remission rates of > 85% with a median event-free survival (EFS) of > 50 months, but with a pattern of continuous relapse out to 60 months. We performed a study of hyper-CVAD + R, followed by consolidative peripheral blood progenitor cells autograft [autologous stem cell transplant (AuSCT)] with high-dose busulfan and melphalan (Bu/Mel) conditioning, in patients with responsive disease. Thirteen patients with a median age of 54 (range = 33-61) were treated. Complete remission (CR) was achieved in 12 patients (92%) after hyper-CVAD + R and 12 completed AuSCT after Bu/Mel conditioning. One patient died during the autograft and another declined AuSCT after achieving a CR with hyper-CVAD + R. With a median follow-up from diagnosis of 36 months (range = 16-53 months), the observed 36 months overall survival and EFS are both 92% for the whole cohort. These data confirm the excellent CR rates achieved by the use of hyper-CVAD + R in patients with MCL and suggest that consolidation with Bu/Mel and AuSCT may improve durable disease control when compared to published outcomes of hyper-CVAD + R alone.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1432-0584
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
86
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
101-5
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:17089127-Adult, pubmed-meshheading:17089127-Antibodies, Monoclonal, pubmed-meshheading:17089127-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:17089127-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17089127-Busulfan, pubmed-meshheading:17089127-Cyclophosphamide, pubmed-meshheading:17089127-Dexamethasone, pubmed-meshheading:17089127-Disease-Free Survival, pubmed-meshheading:17089127-Doxorubicin, pubmed-meshheading:17089127-Female, pubmed-meshheading:17089127-Follow-Up Studies, pubmed-meshheading:17089127-Humans, pubmed-meshheading:17089127-Lymphoma, Mantle-Cell, pubmed-meshheading:17089127-Male, pubmed-meshheading:17089127-Melphalan, pubmed-meshheading:17089127-Middle Aged, pubmed-meshheading:17089127-Neoplasm Staging, pubmed-meshheading:17089127-Stem Cell Transplantation, pubmed-meshheading:17089127-Survival Rate, pubmed-meshheading:17089127-Time Factors, pubmed-meshheading:17089127-Transplantation, Homologous, pubmed-meshheading:17089127-Vincristine
pubmed:year
2007
pubmed:articleTitle
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
pubmed:affiliation
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. david.ritchie@petermac.org
pubmed:publicationType
Journal Article, Clinical Trial